Business
Karyopharm Announces Updated Selinexor Data in Patients with Treatment-Naïve Myelofibrosis to be Presented at AACR 2023
NEWTON, Mass., March 14, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"NEWTON, Mass., March 14, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that results from its Phase 1 study evaluating the safety and efficacy of once-weekly selinexor in combination with standard dose ruxolitinib in patients with treatment-naïve myelofibrosis (NCT04562389) have been selected for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023 in Orlando, Florida.\n\n \n \n \n \n \n \n\n \nPrevious updates of the Phase 1 study showed that the combination of selinexor and ruxolitinib was generally well tolerated, with improvements in spleen and symptom responses and hemoglobin stabilization. Updated efficacy, including ≥35% reduction in spleen volume (SVR35) and ≥50% reduction in symptom scores (TSS50), and safety data will be presented from the 24 treatment-naïve myelofibrosis patients enrolled in this study, all of whom have been followed for at least 24 weeks. \n\"We remain highly encouraged by the efficacy and safety observed with selinexor in combination with ruxolitinib in patients with treatment-naïve myelofibrosis and look forward to presenting updated data from this Phase 1 study at AACR 2023. The data underscore the potential importance of XPO1 inhibition in myelofibrosis,\" said Reshma Rangwala, MD, PhD, Chief Medical Officer of Karyopharm.\nThe Company plans to hold an investor webcast to discuss the updated results from this study.\nDetails for the AACR abstract\nTitle: A Phase 1, Open-Label, Dose-Escalation Study of Selinexor Plus Ruxolitinib in Patients with Treatment-Naïve MyelofibrosisAbstract Presentation Number: CT261Session Title: Phase I Clinical Trials 2Session Date and Time: Tuesday April 18, 2023, 1:30pm -5:00pm (ET)\nAbout XPOVIO® (selinexor)\nXPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds to be approved for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved in the U.S. and marketed by Karyopharm in multiple oncology indications, including: (i) in combination with Velcade® (bortezomib) and dexamethasone (XVd) in patients with multiple mye...